SARcode Corporation To Present Phase 2 Clinical Data For Dry Eye Candidate At The ARVO2011 Annual Meeting
SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1-May 5, 2011, in Fort Lauderdale, Florida. SAR 1118 is an investigational novel small-molecule topical therapy that inhibits T-cell mediated inflammation, a key component of dry eye syndrome.